Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.76 Insider Own0.50% Shs Outstand111.91M Perf Week-0.43%
Market Cap13.64B Forward P/E- EPS next Y-7.20 Insider Trans-26.98% Shs Float110.72M Perf Month30.97%
Income-821.40M PEG- EPS next Q-2.23 Inst Own98.50% Short Float5.68% Perf Quarter41.39%
Sales169.10M P/S80.63 EPS this Y-39.80% Inst Trans1.74% Short Ratio8.59 Perf Half Y74.06%
Book/sh14.78 P/B8.24 EPS next Y9.30% ROA-37.10% Target Price124.95 Perf Year58.87%
Cash/sh15.38 P/C7.92 EPS next 5Y46.09% ROE-52.90% 52W Range60.27 - 125.72 Perf YTD67.11%
Dividend- P/FCF- EPS past 5Y-39.20% ROI-59.70% 52W High-5.35% Beta2.43
Dividend %- Quick Ratio5.20 Sales past 5Y9.70% Gross Margin91.40% 52W Low97.44% ATR4.33
Employees1065 Current Ratio5.40 Sales Q/Q3286.20% Oper. Margin- RSI (14)67.70 Volatility3.28% 4.14%
OptionableYes Debt/Eq0.00 EPS Q/Q21.20% Profit Margin- Rel Volume0.42 Prev Close121.84
ShortableYes LT Debt/Eq0.00 EarningsOct 31 BMO Payout- Avg Volume732.36K Price119.00
Recom1.90 SMA208.15% SMA5025.59% SMA20042.98% Volume204,772 Change-2.33%
Nov-20-19Initiated Oppenheimer Outperform $128
Nov-13-19Initiated BofA/Merrill Buy $110
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Dec-11-19 05:29AM  Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested' American City Business Journals
Dec-04-19 04:53PM  Trade of the 2020's: Sell Gold, Buy Biotech Zacks
Dec-03-19 04:54PM  Alnylam Pharmaceuticals, Inc. (ALNY): These Hedge Funds Cashed Out Too Early Insider Monkey
Dec-02-19 08:12AM  Alnylam Pharmaceuticals (NASDAQ:ALNY) Is In A Strong Position To Grow Its Business Simply Wall St.
Nov-29-19 11:30AM  The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG Zacks
09:34AM  Alnylam Gets Second Product Approval Amid Stiff Competition Zacks
Nov-27-19 05:33PM  Why Gold is Headed to Zero -- And What You Should Buy Instead Zacks
Nov-26-19 09:39AM  Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue? Zacks +5.91%
08:00AM  Alnylam to Webcast Presentations at Upcoming December Investor Conferences TEST Business Wire Releases
08:00AM  Alnylam to Webcast Presentations at Upcoming December Investor Conferences Business Wire
Nov-25-19 09:42AM  The Medicines Company to be Acquired by Novartis for $9.7B Zacks +5.15%
08:37AM  Novartis Is Buying The Medicines Company for $9.7 Billion Barrons.com
Nov-22-19 07:00AM  Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day Business Wire
Nov-21-19 09:54AM  Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria Zacks
09:01AM  Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% Zacks
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:53PM  Alnylam shares jump on FDA approval MarketWatch +10.50%
02:21PM  Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI (givosiran) Business Wire
02:03PM  Alnylam Announces Approval of GIVLAARI (givosiran) by the U.S. Food and Drug Administration (FDA) Business Wire
01:22PM  UPDATE 2-Alnylam's rare genetic disorder drug priced at $575,000 per year Reuters
01:02PM  FDA gives early OK to Alnylam rare disease drug American City Business Journals
12:47PM  U.S. FDA approves Alnylam's drug for rare genetic disorder Reuters
08:41AM  Medicines Company Up on Rumors of Potential Buyout by Novartis Zacks
Nov-19-19 08:00AM  Alnylam Announces Second Annual Advocacy for Impact Grants Program Business Wire +5.61%
Nov-18-19 10:27AM  Medicines Company Posts Full Inclisiran Data From ASCVD Study Zacks
Nov-12-19 04:00PM  Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference Business Wire
Nov-09-19 12:00PM  Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study Business Wire
Nov-07-19 10:00AM  Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy? Zacks
Nov-06-19 09:00AM  Alnylam (ALNY) Upgraded to Buy: Here's Why Zacks
04:08AM  Edited Transcript of ALNY earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 11:56AM  Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength Zacks
Nov-01-19 10:34AM  Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates Zacks
Oct-31-19 11:54AM  Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss Zacks
09:15AM  Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:00AM  Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity Business Wire
06:30AM  Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
Oct-30-19 12:44PM  Guardant Health (GH) to Report Q3 Earnings: What's in Store? Zacks
08:30AM  Why Earnings Season Could Be Great for Alnylam (ALNY) Zacks
Oct-29-19 09:46AM  Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store? Zacks
Oct-25-19 12:12PM  Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? Zacks
Oct-24-19 02:11PM  Alnylam Named #1 Biopharma Employer by Science Magazine Business Wire
10:32AM  Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
10:06AM  Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3 Zacks
Oct-23-19 08:00AM  Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results Business Wire
Oct-22-19 04:05PM  Hedge Funds Have Never Been More Bullish On Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Oct-16-19 09:15AM  Earnings Season Makes Good First Impression Zacks
Oct-15-19 06:00AM  Alnylams Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society Business Wire
Oct-10-19 07:30AM  Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire
Oct-01-19 06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals -7.35%
Sep-27-19 07:27AM  If You Had Bought Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Three Years Ago You'd Have Made 14% Simply Wall St.
Sep-26-19 12:05PM  Medicines Company's Inclisiran Succeeds in Pivotal Studies Zacks
08:30AM  Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference Business Wire
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
Sep-19-19 11:02AM  Alnylam Focuses on Pipeline Development Amid Competition Zacks
Sep-17-19 10:27AM  Alnylam Begins Phase III Study on Onpattro for New Indication Zacks
Sep-16-19 07:30AM  Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Business Wire
Sep-13-19 09:00AM  What Makes Alnylam (ALNY) a New Buy Stock Zacks
07:30AM  Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy Business Wire
Sep-11-19 08:30AM  1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day Business Wire
Sep-10-19 05:30AM  Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias Business Wire
Sep-09-19 09:31AM  3 Biotech Stocks That Could Soar This Week Motley Fool
Sep-06-19 03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
07:30AM  Alnylam to Host Sixth Annual RNAi Roundtable Webcast Series Business Wire
Sep-05-19 09:31AM  Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report? Zacks
Sep-04-19 10:17AM  Biotech vet George Scangos steers new company toward nine-figure IPO American City Business Journals
Sep-03-19 04:15PM  This Biotech Stock Is Looking To Leapfrog Its Rivals And Buy Point Investor's Business Daily
01:47PM  This Biotech Stock Is Looking To Leapfrog Its Rivals And Buy Point Investor's Business Daily
Sep-02-19 03:13PM  The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight Benzinga
Aug-30-19 08:00AM  Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference Business Wire
Aug-28-19 03:16PM  Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
Aug-27-19 11:19AM  Medicines Company's Inclisiran Succeeds in Pivotal Study Zacks
Aug-26-19 05:43PM  Heres Why The Medicines Company Shares Jumped 13.8% Today Motley Fool
Aug-15-19 09:00AM  BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
08:28AM  Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe Zacks
Aug-14-19 09:21AM  Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks
08:00AM  Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias Business Wire
Aug-13-19 07:30AM  Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
07:30AM  Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
Aug-12-19 04:13PM  Alnylam Adds on Sales, Looks to Pipeline for Further Growth Motley Fool
11:07AM  Edited Transcript of ALNY earnings conference call or presentation 6-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-07-19 08:13AM  Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates Zacks +8.23%
Aug-06-19 03:23PM  Alnylam Pharmaceuticals Inc (ALNY) Q2 2019 Earnings Call Transcript Motley Fool
01:09PM  Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid Zacks
08:55AM  Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:30AM  Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity Business Wire
07:22AM  The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering Benzinga
Aug-05-19 04:00PM  Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria Business Wire
Aug-02-19 11:12AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat Zacks
10:28AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2 Zacks
Aug-01-19 09:54AM  Amgen (AMGN) Catches Eye: Stock Jumps 5.7% Zacks
Jul-30-19 10:38AM  Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q2 Earnings Expected to Decline Zacks
Jul-29-19 10:08AM  A Look At The Fair Value Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Simply Wall St.
Jul-26-19 10:38AM  Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks
Jul-25-19 11:25AM  Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View Zacks
Jul-24-19 01:54PM  Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Jul-23-19 04:00PM  Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results Business Wire
07:00AM  Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada CNW Group
Jul-19-19 09:41AM  Horizon's NDA for Procysbi New Dosage Form Accepted by FDA Zacks
Jul-16-19 07:00AM  Alnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis Business Wire
Jul-11-19 09:05AM  Horizon Therapeutics Files BLA to FDA for Eye Disease Drug Zacks
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenstreet YvonneChief Operating OfficerNov 20Option Exercise42.228,404354,81710,320Nov 22 04:05 PM
Fanucci MarshaDirectorNov 20Option Exercise13.8075,0001,035,00075,000Nov 22 04:06 PM
Fanucci MarshaDirectorNov 20Sale100.0075,0007,500,0000Nov 22 04:06 PM
Greenstreet YvonneChief Operating OfficerNov 20Sale105.008,404882,4201,916Nov 22 04:05 PM
SHARP PHILLIP ADirectorNov 18Option Exercise16.4315,000246,450250,633Nov 20 04:17 PM
SHARP PHILLIP ADirectorNov 18Sale91.7115,0001,375,662235,633Nov 20 04:17 PM
Greene Barry EPresidentOct 22Option Exercise16.4358,913967,941111,851Oct 24 04:04 PM
Greene Barry EPresidentOct 22Sale89.9958,9135,301,58152,938Oct 24 04:04 PM
MARAGANORE JOHNChief Executive OfficerOct 14Option Exercise16.4349,456812,562239,449Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerOct 14Sale79.4549,4563,929,210189,993Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerMay 15Option Exercise16.4349,457812,579239,450May 17 04:07 PM
MARAGANORE JOHNChief Executive OfficerMay 15Sale70.0049,4573,461,990189,993May 17 04:07 PM
SHARP PHILIP ADirectorApr 15Option Exercise22.0915,000331,350250,633Apr 17 04:05 PM
SHARP PHILIP ADirectorApr 15Sale88.2315,0001,323,442235,633Apr 17 04:05 PM